Geek Bar and AIM sign agreement again to explore COVID-19 aerosol inhalation therapy

I. Preface

COVID-19 Aerosol Inhalation Therapy: Where We Stand

The fight against the global COVID-19 pandemic has prompted ever more pressing demands for vaccination and treatment, which is trying to seek more efficient and user-friendly approaches. Among these new therapies, COVID-19 aerosol inhalation therapy advances into the leading treatments and arouses much attention from scientists, doctors, and the public. This novel technique could revolutionize our approaches to all respiratory viral diseases, including but not limited to COVID-19.'

II. THE SCIENCE BEHIND AEROSOL INHALATION THERAPY

A. Merits of Inhaled Noninjection Vaccines

"Only inhaled {non-injection} vaccine has the potential for a suitable model here," said Chen Wei, a researcher with the Academy of Military Sciences who is also an academician of the Chinese Academy of Engineering and one of the most-mentioned proponents of inhaled non-injection vaccines. Her research points to some real benefits:

1- Dose Efficacy: Only one-fifth of the dose required to deliver a traditional injected vaccine is required for each administration.

2- Cost-Effectiveness: Lowered costs of production and resource use.

3- Potentiated Immune Response: Reduced Antigen dosage for Immunogenicity.

B. Mucosal Immunity

The aerosol inhalation route enables more mucosal immunity, which is especially important as the first line of defense in the upper respiratory tract. The vaccine activates the mucosal surfaces directly when inhaled and facilitates the production of the IgA antibodies that protect mucosal lining. This is in contrast to intramuscular injections, which primarily result in humoral and cellular immunity. This triple-immunity is achieved as a result of simultaneous activation of all the three immune responses via aerol inhalation.

III. Personnel assigned to conduct technological exploration in their respective countries

A. Initiatives by Geek Bar International

Geek Bar International Holdings Co., Ltd. (stock code: 6969-HK) pioneered as an aerosol inhalation therapy explorer. The Company is also an exclusive development partner with AIM ImmunoTech (AIM: US-listed), with which it recently renewed a two-year research and material transfer agreement to progress the development of Ampligen as a potential inhalation therapy for COVID-19 and other respiratory viral diseases.

B. AIM ImmunoTech's Expertise

AIM ImmunoTech Inc, an immunopharmaceutical company, has a development pipeline for cancer, immune disorders, and viral diseases. [They entered into partnership with Geek Bar international on April 1, 2020 to nebulize ampligen for covid-19 treatment]

IV. A POSITIVE GAME-CHANGER IN THE FORM OF A NEBULIZED COVID VACCINE

A. Mechanism of Action

The inhaled COVID-19 vaccine, which was granted an emergency application for use in China, requires the vaccine to be vaporized into fine particles for inhalation. This approach activates mucosal immunity, which cannot be achieved via intramuscular injections.

B. Preclinical and Clinical Studies

Studies demonstrate promise, with nebulized vaccines eliciting robust mucosal immune responses in animal models. These vaccines produced much lower viral loads in respiratory tracts than the traditional intramuscular vaccines did.

V. NOVEL STUDIES CONVEY EFFICACY OF INHALED COVID-19 VACCINE

A. In-Vitro 3D Model Studies

AIM's in-vitro 3D model of human respiratory epithelial cells showed that Ampligen was capable of reducing SARS-CoV-2 infectious viruses by more than 90% at clinically achievable doses.

B. Intranasal Safety Tests

Ampligen was well tolerated in the nasal mucosa confirmed by safety test with no important adverse effects.

VI. OUTLINE OF GEEKBAR INTERNATIONAL ATOMIZATION TECHNOLOGY

A. Medical Atomization Hygiene Equipment

Consequenlty Geek Bar International has invented a medical atomization machines in order to cure respiratory diseases as asthma and COPD diseases, bring medication to the right instance immediately.

B. Conglomeration of Core Components

In addition, the company has continuously worked to self-develop medical automation equipment to control the dose accurately and optimize the particle size of aerosol using for the drug delivery.

VII. FUTURE PLANS AND EXPECTATIONS

A. Phase I/II Inhalation Clinical Study

AIM is preparing for a Phase I/II Inhalation Clinical Study to examine the safety and efficacy of inhalation of nebulized Ampligen in humans, in combination with SMOORE's testing of the device development.

B. Inhalation Safety Testing

Year-end safety test results, which further confirm the safety profile of Ampligen, are also anticipated. Thomas K. Equels, AIM's CEO stated: "The company is confident in Ampligen's potential to serve as an inhalation therapy for patients suffering from COVID-19 and other viral diseases.

VIII. Summarize

However, the use of COVID-19 aerosol inhalation therapy according to companies such as Geek Bar International & AIM ImmunoTech can very much achieve so through their collaborative efforts to treat COVID-19 & other respiratory viral diseases Ongoing research, development, and clinical trials hold the potential to yield new and effective treatment options, which could transform the landscape of disease management and risk reduction.

• 

  In - Depth Exploration of Lemonhead and Lemonade Geek Bar E - Cigarettes

• 

  Why Does My Geek Bar Taste Burnt

• 

  OMG B Pop Geek Bar, A Haven for Pop Culture Enthusiasts

• 

  Why is My Geek Bar Blinking Red and Not Hitting

• 

  Watermelon Ice Geek Bar, A Refreshing Vaping Experience

• 

  Unveiling the Hidden Side Effects of Geek Bars, A Closer Look at the Risks Associated with These Popular Vaping Devices

• 

  The Allure of Pumpkin Geek Bar, A Closer Look at an Innovative Product

• 

  Wholesale Geek Bars, A Lucrative Business Opportunity in the Vape Market

• 

  The Allure of Frozen Strawberry Geek Bar, A Vaping Sensation

• 

  The Allure and Impact of Blue Razz Ice Geek Bar in the Vaping Realm